FDA Approves Product Under Voucher for Rare Pediatric Disease Priority Review Voucher

Summary

The FDA has approved a product redeeming a priority review voucher for ULTOMIRIS (ravulizumab-cwvz), a rare pediatric disease treatment, following the issuance of a notice by the agency. The approval is based on the product's meeting the criteria for a rare pediatric disease product application.